These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24126578)

  • 21. Dormant Mycobacterium tuberculosis converts isoniazid to the active drug in a Wayne's model of dormancy.
    Raghunandanan S; Jose L; Kumar RA
    J Antibiot (Tokyo); 2018 Nov; 71(11):939-949. PubMed ID: 30185901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Mycobacterium smegmatis as a possible surrogate screen for selecting molecules active against multi-drug resistant Mycobacterium tuberculosis.
    Chaturvedi V; Dwivedi N; Tripathi RP; Sinha S
    J Gen Appl Microbiol; 2007 Dec; 53(6):333-7. PubMed ID: 18187888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A high content screening assay for identifying inhibitors against active and dormant state intracellular Mycobacterium tuberculosis.
    Yeware A; Agrawal S; Sarkar D
    J Microbiol Methods; 2019 Sep; 164():105687. PubMed ID: 31415793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human mesenchymal stem cell based intracellular dormancy model of Mycobacterium tuberculosis.
    Singh VK; Mishra A; Bark S; Mani A; Subbian S; Hunter RL; Jagannath C; Khan A
    Microbes Infect; 2020 Oct; 22(9):423-431. PubMed ID: 32562667
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
    De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
    J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.
    Vilchèze C; Kim J; Jacobs WR
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29298757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.
    Villar R; Vicente E; Solano B; Pérez-Silanes S; Aldana I; Maddry JA; Lenaerts AJ; Franzblau SG; Cho SH; Monge A; Goldman RC
    J Antimicrob Chemother; 2008 Sep; 62(3):547-54. PubMed ID: 18502817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] analogues against both active and dormant Mycobacterium tuberculosis.
    Alluri KK; Reshma RS; Suraparaju R; Gottapu S; Sriram D
    Bioorg Med Chem; 2018 May; 26(8):1462-1469. PubMed ID: 29501415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis.
    Coulibaly S; Cimino M; Ouattara M; Lecoutey C; Buchieri MV; Alonso-Rodriguez N; Briffotaux J; Mornico D; Gicquel B; Rochais C; Dallemagne P
    Eur J Med Chem; 2020 Dec; 207():112821. PubMed ID: 32950907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of New MmpL3 Inhibitors by Untargeted and Targeted Mutant Screens Defines MmpL3 Domains with Differential Resistance.
    Williams JT; Haiderer ER; Coulson GB; Conner KN; Ellsworth E; Chen C; Alvarez-Cabrera N; Li W; Jackson M; Dick T; Abramovitch RB
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31405862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.
    Desai NC; Somani H; Trivedi A; Bhatt K; Nawale L; Khedkar VM; Jha PC; Sarkar D
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1776-83. PubMed ID: 26920799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy.
    Vilchèze C; Copeland J; Keiser TL; Weisbrod T; Washington J; Jain P; Malek A; Weinrick B; Jacobs WR
    mBio; 2018 May; 9(3):. PubMed ID: 29844114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis.
    Zhang M; Sala C; Hartkoorn RC; Dhar N; Mendoza-Losana A; Cole ST
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5782-9. PubMed ID: 22926567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-vitro antimycobacterial activity of new synthetic amidrazone derivatives.
    Banfi E; Mamolo MG; Vio L; Predominato M
    J Chemother; 1993 Jun; 5(3):164-7. PubMed ID: 8371125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.
    Iona E; Giannoni F; Pardini M; Brunori L; Orefici G; Fattorini L
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1537-40. PubMed ID: 17242153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.
    Hurdle JG; Lee RB; Budha NR; Carson EI; Qi J; Scherman MS; Cho SH; McNeil MR; Lenaerts AJ; Franzblau SG; Meibohm B; Lee RE
    J Antimicrob Chemother; 2008 Nov; 62(5):1037-45. PubMed ID: 18693235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis.
    Zhang M; Sala C; Dhar N; Vocat A; Sambandamurthy VK; Sharma S; Marriner G; Balasubramanian V; Cole ST
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3217-23. PubMed ID: 24663022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Antimycobacterial Compounds Suppress NAD Biogenesis by Targeting a Unique Pocket of NaMN Adenylyltransferase.
    Osterman AL; Rodionova I; Li X; Sergienko E; Ma CT; Catanzaro A; Pettigrove ME; Reed RW; Gupta R; Rohde KH; Korotkov KV; Sorci L
    ACS Chem Biol; 2019 May; 14(5):949-958. PubMed ID: 30969758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.